Does the media favor HIMS or GH?

In the previous week, Hims & Hers Health had 14 more articles in the media than Guardant Health. MarketBeat recorded 23 mentions for Hims & Hers Health and 9 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.61 beat Hims & Hers Health's score of 0.58 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Guardant Health 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer HIMS or BTSG?

In the previous week, Hims & Hers Health had 16 more articles in the media than BrightSpring Health Services. MarketBeat recorded 23 mentions for Hims & Hers Health and 7 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.14 beat Hims & Hers Health's score of 0.58 indicating that BrightSpring Health Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BrightSpring Health Services 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FMS or HIMS?

In the previous week, Hims & Hers Health had 22 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 23 mentions for Hims & Hers Health and 1 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 0.98 beat Hims & Hers Health's score of 0.58 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fresenius Medical Care AG & Co. KGaA 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, HIMS or PACS?

PACS Group has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 3.49 $128.37M -$0.09 N/A PACS Group $5.29B 1.10 $191.54M $1.56 23.51

Does the media favor HIMS or PACS?

In the previous week, Hims & Hers Health had 17 more articles in the media than PACS Group. MarketBeat recorded 23 mentions for Hims & Hers Health and 6 mentions for PACS Group. Hims & Hers Health's average media sentiment score of 0.58 beat PACS Group's score of -0.16 indicating that Hims & Hers Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CAI or HIMS?

In the previous week, Hims & Hers Health had 19 more articles in the media than Caris Life Sciences. MarketBeat recorded 23 mentions for Hims & Hers Health and 4 mentions for Caris Life Sciences. Hims & Hers Health's average media sentiment score of 0.58 beat Caris Life Sciences' score of 0.20 indicating that Hims & Hers Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hims & Hers Health (HIMS) Competitors

$35.44 -0.03 (-0.08%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$35.25 -0.19 (-0.54%)

As of 06/18/2026 08:00 PM Eastern

Compare

HIMS vs. GH, BTSG, FMS, PACS, and CAI

Should you buy Hims & Hers Health stock or one of its competitors? MarketBeat compares Hims & Hers Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hims & Hers Health include Guardant Health (GH), BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), PACS Group (PACS), and Caris Life Sciences (CAI). These companies are all part of the "healthcare" industry.

How does Hims & Hers Health compare to Guardant Health?

Hims & Hers Health (NYSE:HIMS) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Hims & Hers Health currently has a consensus price target of $29.37, indicating a potential downside of 17.14%. Guardant Health has a consensus price target of $141.95, indicating a potential upside of 7.72%. Given Guardant Health's stronger consensus rating and higher probable upside, analysts plainly believe Guardant Health is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	3 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.06
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 5.6% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Hims & Hers Health has a net margin of -0.56% compared to Guardant Health's net margin of -40.10%. Hims & Hers Health's return on equity of 6.10% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Guardant Health	-40.10%	N/A	-26.42%

Hims & Hers Health has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market. Comparatively, Guardant Health has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

In the previous week, Hims & Hers Health had 14 more articles in the media than Guardant Health. MarketBeat recorded 23 mentions for Hims & Hers Health and 9 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.61 beat Hims & Hers Health's score of 0.58 indicating that Guardant Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	11 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Guardant Health	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Hims & Hers Health has higher revenue and earnings than Guardant Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	3.49	$128.37M	-$0.09	N/A
Guardant Health	$982.02M	17.79	-$416.28M	-$3.39	N/A

Summary

Hims & Hers Health beats Guardant Health on 9 of the 17 factors compared between the two stocks.

How does Hims & Hers Health compare to BrightSpring Health Services?

Hims & Hers Health (NYSE:HIMS) and BrightSpring Health Services (NASDAQ:BTSG) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

BrightSpring Health Services has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	3.49	$128.37M	-$0.09	N/A
BrightSpring Health Services	$12.91B	1.01	$190.67M	$1.41	46.99

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 2.8% of BrightSpring Health Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Hims & Hers Health currently has a consensus target price of $29.37, suggesting a potential downside of 17.14%. BrightSpring Health Services has a consensus target price of $59.60, suggesting a potential downside of 10.04%. Given BrightSpring Health Services' stronger consensus rating and higher possible upside, analysts clearly believe BrightSpring Health Services is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	3 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.06
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.11

In the previous week, Hims & Hers Health had 16 more articles in the media than BrightSpring Health Services. MarketBeat recorded 23 mentions for Hims & Hers Health and 7 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.14 beat Hims & Hers Health's score of 0.58 indicating that BrightSpring Health Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	11 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BrightSpring Health Services	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, BrightSpring Health Services has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market.

BrightSpring Health Services has a net margin of 2.27% compared to Hims & Hers Health's net margin of -0.56%. BrightSpring Health Services' return on equity of 14.63% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
BrightSpring Health Services	2.27%	14.63%	4.41%

Summary

BrightSpring Health Services beats Hims & Hers Health on 12 of the 17 factors compared between the two stocks.

How does Hims & Hers Health compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Fresenius Medical Care AG & Co. KGaA has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market.

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $28.00, suggesting a potential upside of 18.69%. Hims & Hers Health has a consensus target price of $29.37, suggesting a potential downside of 17.14%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, equities research analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	5 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.44
Hims & Hers Health	3 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.06

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.88% compared to Hims & Hers Health's net margin of -0.56%. Fresenius Medical Care AG & Co. KGaA's return on equity of 8.90% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%
Hims & Hers Health	-0.56%	6.10%	1.52%

8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Hims & Hers Health had 22 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 23 mentions for Hims & Hers Health and 1 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 0.98 beat Hims & Hers Health's score of 0.58 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fresenius Medical Care AG & Co. KGaA	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	11 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$22.20B	0.57	$1.11B	$1.90	12.42
Hims & Hers Health	$2.35B	3.49	$128.37M	-$0.09	N/A

Summary

Fresenius Medical Care AG & Co. KGaA beats Hims & Hers Health on 9 of the 16 factors compared between the two stocks.

How does Hims & Hers Health compare to PACS Group?

Hims & Hers Health (NYSE:HIMS) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Hims & Hers Health currently has a consensus target price of $29.37, suggesting a potential downside of 17.14%. PACS Group has a consensus target price of $48.00, suggesting a potential upside of 30.88%. Given PACS Group's stronger consensus rating and higher possible upside, analysts clearly believe PACS Group is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	3 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.06
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

PACS Group has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	3.49	$128.37M	-$0.09	N/A
PACS Group	$5.29B	1.10	$191.54M	$1.56	23.51

63.5% of Hims & Hers Health shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 70.1% of PACS Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

PACS Group has a net margin of 4.49% compared to Hims & Hers Health's net margin of -0.56%. PACS Group's return on equity of 26.47% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
PACS Group	4.49%	26.47%	4.36%

In the previous week, Hims & Hers Health had 17 more articles in the media than PACS Group. MarketBeat recorded 23 mentions for Hims & Hers Health and 6 mentions for PACS Group. Hims & Hers Health's average media sentiment score of 0.58 beat PACS Group's score of -0.16 indicating that Hims & Hers Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	11 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PACS Group beats Hims & Hers Health on 11 of the 15 factors compared between the two stocks.

How does Hims & Hers Health compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Hims & Hers Health (NYSE:HIMS) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

In the previous week, Hims & Hers Health had 19 more articles in the media than Caris Life Sciences. MarketBeat recorded 23 mentions for Hims & Hers Health and 4 mentions for Caris Life Sciences. Hims & Hers Health's average media sentiment score of 0.58 beat Caris Life Sciences' score of 0.20 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hims & Hers Health	11 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences presently has a consensus target price of $27.56, indicating a potential upside of 49.19%. Hims & Hers Health has a consensus target price of $29.37, indicating a potential downside of 17.14%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Caris Life Sciences is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Hims & Hers Health	3 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.06

Caris Life Sciences has a net margin of 3.75% compared to Hims & Hers Health's net margin of -0.56%. Caris Life Sciences' return on equity of 98.28% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Hims & Hers Health	-0.56%	6.10%	1.52%

Hims & Hers Health has higher revenue and earnings than Caris Life Sciences. Hims & Hers Health is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	6.43	-$68.09M	-$7.61	N/A
Hims & Hers Health	$2.35B	3.49	$128.37M	-$0.09	N/A

63.5% of Hims & Hers Health shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Caris Life Sciences beats Hims & Hers Health on 9 of the 15 factors compared between the two stocks.

Get Hims & Hers Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIMS vs. The Competition

Export

Metric	Hims & Hers Health	MEDICAL INFO SYS Industry	Medical Sector	NYSE Exchange
Market Cap	$8.20B	$1.58B	$6.38B	$23.18B
Dividend Yield	N/A	N/A	2.68%	4.07%
P/E Ratio	-393.79	77.84	24.54	31.61
Price / Sales	3.49	7.59	574.69	22.84
Price / Cash	38.10	23.32	44.20	24.10
Price / Book	14.89	5.12	10.83	4.68
Net Income	$128.37M	-$54.76M	$3.57B	$1.08B
7 Day Performance	32.00%	3.26%	0.71%	-0.82%
1 Month Performance	57.76%	2.42%	3.97%	3.12%
1 Year Performance	-41.99%	-1.62%	28.54%	24.66%

Hims & Hers Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIMS Hims & Hers Health	2.8006 of 5 stars	$35.44 -0.1%	$29.37 -17.1%	-42.0%	$8.20B	$2.35B	N/A	2,442	Analyst Forecast Insider Trade Gap Down
GH Guardant Health	2.1363 of 5 stars	$131.80 +1.3%	$139.80 +6.1%	+160.6%	$17.46B	$982.02M	N/A	2,506
BTSG BrightSpring Health Services	4.2146 of 5 stars	$61.52 +0.9%	$58.53 -4.9%	+196.0%	$12.12B	$12.91B	43.57	23,500	Positive News Analyst Forecast
FMS Fresenius Medical Care AG & Co. KGaA	4.2994 of 5 stars	$22.41 +0.3%	$28.00 +24.9%	-12.3%	$12.10B	$22.20B	11.79	1,488
PACS PACS Group	3.7807 of 5 stars	$35.84 +1.8%	$48.00 +33.9%	+174.8%	$5.68B	$5.29B	23.02	47,455	News Coverage Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HIMS) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hims & Hers Health (HIMS) Competitors

HIMS vs. GH, BTSG, FMS, PACS, and CAI

How does Hims & Hers Health compare to Guardant Health?

Summary

How does Hims & Hers Health compare to BrightSpring Health Services?

Summary

How does Hims & Hers Health compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Hims & Hers Health compare to PACS Group?

Summary

How does Hims & Hers Health compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIMS vs. The Competition

Hims & Hers Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hims & Hers Health (HIMS) Competitors

HIMS vs. GH, BTSG, FMS, PACS, and CAI

How does Hims & Hers Health compare to Guardant Health?

Do analysts recommend HIMS or GH?

Do insiders & institutionals have more ownership in HIMS or GH?

Is HIMS or GH more profitable?

Which has more volatility and risk, HIMS or GH?

Does the media favor HIMS or GH?

Which has higher valuation and earnings, HIMS or GH?

Summary

How does Hims & Hers Health compare to BrightSpring Health Services?

Which has preferable earnings and valuation, HIMS or BTSG?

Do institutionals & insiders have more ownership in HIMS or BTSG?

Do analysts recommend HIMS or BTSG?

Does the media prefer HIMS or BTSG?

Which has more volatility & risk, HIMS or BTSG?

Is HIMS or BTSG more profitable?

Summary

How does Hims & Hers Health compare to Fresenius Medical Care AG & Co. KGaA?

Which has more volatility and risk, FMS or HIMS?

Do analysts rate FMS or HIMS?

Is FMS or HIMS more profitable?

Do institutionals & insiders have more ownership in FMS or HIMS?

Does the media favor FMS or HIMS?

Which has stronger earnings & valuation, FMS or HIMS?

Summary

How does Hims & Hers Health compare to PACS Group?

Do analysts rate HIMS or PACS?

Which has better earnings and valuation, HIMS or PACS?

Do insiders & institutionals have more ownership in HIMS or PACS?

Is HIMS or PACS more profitable?

Does the media favor HIMS or PACS?

Summary

How does Hims & Hers Health compare to Caris Life Sciences?

Does the media prefer CAI or HIMS?

Do analysts rate CAI or HIMS?

Is CAI or HIMS more profitable?

Which has better earnings and valuation, CAI or HIMS?

Do institutionals and insiders believe in CAI or HIMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIMS vs. The Competition

Hims & Hers Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools